Magister Public Health - MPH (Public Health) / Approximately 6% of all people living with HIV in 2016 are adolescents aged 10-19 years. It is reported globally that adolescents on antiretroviral therapy (ART) are at increased risk for poor retention in care, adherence and viral load suppression, compared to children and adults.

Redução da densidade mineral óssea tem sido descrita como uma complicação clínica entre as pessoas vivendo com HIV/AIDS. Entretanto não há dados descrevendo essa alteração entre os pacientes brasileiros. Nosso objetivo foi investigar a prevalência de baixa densidade mineral óssea entre pessoas vivendo com HIV/AIDS na cidade de São Paulo. Nós estudamos108 pacientes infectados pelo HIV (78 homens e 30 mulheres). Foram utilizados neste estudo dados secundários. Os dados foram originalmente coletados com o objetivo de acompanhamento de rotina dos pacientes na clínica e para este estudo estes dados foram coletados dos prontuários médicos. Todos os pacientes foram submetidos ao exame de densitometria óssea, que é uma técnica radiológica que mensura a densidade mineral óssea. Os pacientes foram classificados como tendo baixa densidade mineral óssea de acordo com a classificação da organização mundial da saúde que define osteopenia quando o T-score a partir de -1,1 e osteoporose quando T-score abaixo de -2,5 quando se tratava de homens e mulheres com idade acima de 50 anos. Quando homens e mulheres tinham idade até 50 anos, utilizamos a classificação da ISCO, neste grupo baixa densidade mineral óssea foi definida quando os pacientes apresentavam um Z-score abaixo de -2. Entretanto para este estudo ambas as classificações foram definidas como baixa densidade mineral óssea. A mediana de idade, tempo de infecção pelo HIV a partir da data do diagnóstico, tempo sob terapia antiretroviral, número de células linfócitos TCD4+ no momento da avaliação e Nadir foram similares entre homens e mulheres. A mediana de idade foi de 43 anos (intervalo interquartílico [li] 43-48 anos) e mediana de tempo de infecção pelo HIV foi de 3,66 anos (intervalo interquartílico [li] 1,72- 10,91 anos). Os pacientes tinham adquirido o HIV principalmente pela via sexual (homens que fazem sexo com home 46% e 50% eram heterossexuais). A mediana de células linfócitos TCD4+ foi de 399céls/mm 3(intervalo interquartílico [li] 275 - 566,5). Vinte e cinco pacientes foram classificados como tendo baixa DMO (23,15%). Não houve associação estatisticamente significante entre sexo, IMC, nadir e baixa DMO. Os fatores de risco associados à baixa DMO foram células linfócitos TCD4+ <350 céls/mm3 idade acima de 502 anos e tabagismo (p=0,003; p= 0,001; p=0,002) respectivamente. Quando avaliamos HAART VS baixa DMO encontramos 14,28% de baixa DMO entre os que usavam HAART e 26,25% entre os que não usavam e essa diferença não foi estatisticamente significante. Uma limitação de nosso estudo foi o tamanho de nossa amostra, coortes maiores talvez encontrem resultados diferentes. Contudo, nossos achados fortemente sugerem que a identificação de fatores de risco para baixa DMO e que são modificáveis são um importante componente no manejo desses pacientes para prevenção da baixa DMO e do risco de fratura atribuído a essa alteração. Portanto nossos resultados sugerem que esforços no sentido de encorajamento de cessação do tabagismo devem ser realizados e considerados um importante componente de qualquer programa de saúde dos indivíduos com HIV/AIDS. Identificar fatores de risco modificáveis pode contribuir para formulação de melhores políticas de saúde. / Reductions in bone mineral density (BMD) has been reported as a complication among people living with HIV/AIDS. However, no data describing this complication in Brazilian HIV infected patients have been reported . To investigate the prevalence of osteopenia/osteoporosi s among HIV-infected persons living in Sao Paulo City. We studied 108 HIV-infected patients (78 men and 30 women). We abstracted data from medical charts. All subjects enrolled in this study were submitted to Bone densitometry or dual-X-ray absorptiometry , a radiological technique using low-intensity X-ray . lt measures the bone mineral density content. lf the patients were postmenopausal woman and men aged 50 or above , they were classified as having low bone mineral dens ity when a T-score < -1 at the lumbar spine or femoral neck was detected. lf it was from -1,.1 to -2,5 osteopenia was defined and if it was < -2.5 osteoporosis was defined , using the WHO organization definition. Premenopausal woman and men younger than 50years are classified according to the current ISCO criteria, using Z-score <- 2,0 SD at the lumbar spine or femoral neck. For the propose of this study we combined both classification as Low Bone Mienral Density. Median age was 43 years (IQR 43 - 48 years). and the emdian time since HIV diagnosis was 3,66 years (IQR 1.72 - 10.91). Patients had acquired HIV primarily sexually (men who hasve sex with men 46%, heterosexual 50%). Plasma virai load was undetectable in 53 patients (40.09%) The CD4 T cell count was 399 cells/µ (IQR 275 - 566.5). Twenty-five patients (23.15%) had LBMD. There was no statiscally significant amng gender , body mass índex, nadir and LBMD. The risk factores associetaed were related to having CD4 T cells count <350 mm3 , being older than 50 years and being smoker (p=0.003; p= 0.001; p= 0.002) respectively. Low Bone Mineral Density was encountred 14.28% of patients with HAART, and in 26.25% with no haart. There, HAART was not statistically associated with LBMD. Our study was limited by its small sample. Larger cohort may have different results. Nonetheless, ou finding are compelling and suggesting that addressing modifiable risk factors for low bone mineral density and fragility fractures is an important component of both apporachs. Therefore ou data also suggest that efforts should be directed towards appropriate enouragment of lifestyle change alterations . Specifically , smoking cessation should be a major component of any health program within the HIV/AIDS population. Assessing such risk factors can contribute to the formulation of health policies to address this issue.

Introdução: Estudos apontam maior ocorrência de complicações cardiovasculares na população com HIV/aids. Sabe-se que as alterações iniciais que posteriormente evoluem para doenças cardíacas estão relacionadas às mudanças no perfil inflamatório e oxidativo. Diversas pesquisas, utilizando diferentes populações, demonstraram que os flavonoides presentes no cacau (Theobroma cacao) e na erva mate (Ilex paraguaensis) podem melhorar a função anti-inflamatória e antioxidante do organismo. Objetivo: Avaliar o efeito da ingestão de chocolate e chá mate no perfil inflamatório e oxidativo de pessoas vivendo com HIV/aids (PVHIV/aids) em terapia antirretroviral (TARV). Metodologia: Ensaio clínico do tipo crossover, aleatorizado, cego e controlado por placebo envolvendo 92 voluntários, de 28-59 anos de idade, em tratamento regular com TARV por, no mínimo, 6 meses e com carga viral <50 cópias/mL. Os voluntários consumiram 65g de chocolate em barra (chocolate preto contendo 36g de cacau e placebo) e 3g de chá (erva mate solúvel e placebo) por 15 dias cada, seguido por 15 dias de washout entre cada período de suplementação. Além das variáveis inflamatórias e oxidativas (PCR-us, fibrinogênio, TBARS, HDL-c), foram avaliadas as seguintes características: perfil demográfico e socioeconômico, variáveis antropométricas, imunológicas e prática de atividade física. As análises estatísticas foram realizadas por análise de variância (ANOVA) utilizando o procedimento pkcross no software Stata versão 11.0. O teste t de Student pareado foi feito para comparação das médias dos parâmetros no baseline e pós suplementação. Considerou-se significante p0,05. Resultados: Os participantes eram na maioria do sexo masculino (63,0 por cento ), com média de idade de 45,0 (±7,3) anos. Observou-se média de 13,3 (5±) anos de diagnóstico de HIV, com 10,7 (±5,1) anos de uso de TARV. Quando feita análise por ANOVA houve melhora significativa apenas para o HDL-c (p = 0,05). Entretanto, na comparação entre as variáveis no baseline x chocolate preto, pelo teste t de Student pareado, observou-se aumento de HDL-c (p = 0,01) e diminuição de leucócitos (p = 0,01) e neutrófilos (p = 0,02), e quando comparados os valores das variáveis entre chocolate preto x placebo também houve diferença estatisticamente significativa para HDL-c (p = 0,05), leucócitos (p = 0,01) e neutrófilos (p = 0,03). Conclusão: Este é o primeiro estudo clínico que avaliou o efeito da ingestão de chocolate (cacau) e chá mate (erva mate) no perfil inflamatório e oxidativo de PVHIV em TARV. No presente estudo, o consumo de ambos os suplementos por 15 dias cada, não foi suficiente para melhorar os marcadores do perfil inflamatório e oxidativo destes indivíduos, apesar da alteração significativa de alguns parâmetros relacionados à inflamação e oxidação, como aumento de HDL-c e diminuição de leucócitos e neutrófilos após o consumo do chocolate preto. Tal resultado pode ser devido ao metabolismo diferenciado de PVHIV/aids, o qual sofre alterações não apenas pela própria infecção, mas também pela TARV, a quantidade e biodisponibilidade dos flavonoides nos suplementos e ao tempo de intervenção. / Introduction: There has been an increase on cardiovascular diseases occurrence in the HIV/AIDS population. It is know that initial alterations that after evolve to cardiovascular diseases are related with changes in inflammatory and oxidative disorders. Several studies in other populations demonstrated that flavonoids in cocoa (Theobroma cacao) and yerba mate (Ilex paraguaensis) may improve cardiovascular function due to its antioxidant and anti-inflammatory properties. Objective: To evaluated the effect of chocolate and yerba mate intake on the inflammatory and oxidative profile of people living with HIV/AIDS in antiretroviral therapy (ART). Methodology: Randomized, placebo-controlled, blinded cross-over trial involving 92 volunteers ages 28-59 years, in ART for at least six months and with viral load <50 copies/mL. The volunteers consumed 65g chocolate bar (36g dark chocolate containing cocoa or placebo) and 3g of tea (yerba mate soluble and placebo) for 15 day each, followed by 15 days washout period before the subsequent treatment. In addition to the inflammatory and oxidative variables (us-CRP, fibrinogen, TBARS, HDL-c) the following characteristics were evaluated: demographic and socioeconomic profile, anthropometric variables, immunological and physical activity. Statistical analyzes were performed by the cross-over analyzes of variance (ANOVA) using the procedure pkcross in Stata version 11.0. The paired Student`s t-test was also utilized. A p value 0,05 was considered significant. Results: Patients were mostly male (63 per cent ), with a mean age of 45,0 years. The mean time of HIV/AIDS diagnosis was 13,3 (5±), with 10,7 (±5,1) years of ART. There was statistically significant difference when analyzed by ANOVA only for HDL-c (p = 0,05). However, comparing the variables in the baseline x dark chocolate by the paired Student`s t-test, there were increase in the HDL-c (p = 0,01) and decrease in the leukocyte (p = 0,01) and neutrophil (p = 0,02), and when compared the values of the variables between dark chocolate and placebo also there was statistically significant difference for HDL-c (p = 0,05), leukocyte (p = 0,01) and neutrophil (p = 0,03). Conclusion: This is the first clinical study that evaluated the effect of chocolate (cocoa) and mate tea (yerba mate) consumption on inflammatory and oxidative profile of individuals with HIV/AIDS on ART. In the present study, daily consumption of neither cocoa nor yerba mate for 15 days was sufficient to improve inflammatory and oxidative profile in this group of individuals, despite the increase in HDL-c and decrease of leukocyte and neutrophil values after consumption of dark chocolate. Such an outcome in this group of individuals can be distinguished due to its metabolism, which is altered not only by the infection, but also by the ART, the amount and bioavailability of flavonoids in supplements and timing of intervention.

Measles remains a major global public health problem. Attainment of high population immunity to measles through vaccination is necessary to control this disease. Children infected with HIV infection often experience secondary measles vaccine failure by 2 years of age, making them susceptible to measles. It is not clear whether HIV-infected children on Highly Active Antiretroviral Treatment (HAART), older than 2 years, have a higher risk of measles than HIV-uninfected children. This retrospective cohort study, guided by the proximate determinants framework, was conducted to compare the risk of measles between HIV-infected children on HAART (exposed) and HIV-uninfected peers (unexposed). The age group with the highest measles susceptibility in the exposed children, which could inform timing for revaccination, was investigated. The role of age at initiation of HAART, low CD4+ count, and undernutrition as predictors of the risk of measles in the exposed children was examined. Univariate, bivariate, and binomial logistic regression analytical procedures were used in data analysis. Results showed no significant difference in the risk of measles between exposed and unexposed children. The age groups 5 to 9 years and 2 to 4 years were the first and second most affected by measles among the exposed children. Undernutrition (stunting) was a significant predictor of measles in exposed children (odds ratio of 4.14, p = 0.02), while age at initiation of HAART and CD4+ count prior to measles exposure were not. The study findings provide evidence to inform vaccination policy and nutrition care for HIV-infected children on HAART in Uganda, so as to reduce their risk of measles illness and mortality, thus contributing to positive social change for the children and the country.

<p>Sub-Saharan Africa is home to two thirds of the 33 million HIV infected individuals worldwide. In 2007 there were an estimated 1.5 million Kenyans infected with HIV, and 166 000 new infections in 2008. The introduction of antiretroviral therapy [ART] brought new hope to HIV patients. It has transformed a fatal disease to a chronic manageable condition. Kenya has made great strides in ensuring access to ART and by 2009, 308 610 patients in the country were receiving ART - which is the second highest number worldwide. The success of ART requires a sustained adherence rate to medication of more than 95% to prevent viral replication and the development of drug resistant HIV strains. Identifying the factors that influence adherence, is essential for the long-term success of public ART programmes. The current study explored patient, socio-economic, cultural, and religious and health systems factors that influence adherence to ART at the Coast Provincial General Hospital [CPGH] in Mombasa, Kenya.</p>

<p>Sub-Saharan Africa is home to two thirds of the 33 million HIV infected individuals worldwide. In 2007 there were an estimated 1.5 million Kenyans infected with HIV, and 166 000 new infections in 2008. The introduction of antiretroviral therapy [ART] brought new hope to HIV patients. It has transformed a fatal disease to a chronic manageable condition. Kenya has made great strides in ensuring access to ART and by 2009, 308 610 patients in the country were receiving ART - which is the second highest number worldwide. The success of ART requires a sustained adherence rate to medication of more than 95% to prevent viral replication and the development of drug resistant HIV strains. Identifying the factors that influence adherence, is essential for the long-term success of public ART programmes. The current study explored patient, socio-economic, cultural, and religious and health systems factors that influence adherence to ART at the Coast Provincial General Hospital [CPGH] in Mombasa, Kenya.</p>

Thesis ((Ph.D. (Physiology))--North-West University, Potchefstroom Campus, 2010.

Thesis ((Ph.D. (Physiology))--North-West University, Potchefstroom Campus, 2010.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 5 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 4 uppsatser.